Twice-yearly depemokimab is well-tolerated in randomised, double-blind, placebo-controlled Phase III SWIFT and ANCHOR studies
作者
Oliver Pfaar,Marjolein Cornet,ARNAUD AB BOURDIN,Nicholas Bird,D Edwards,Natalia Karkoszka,Richard Follows,David R. Muccino,Anna Vichiendilokkul,Laura Walrave,Peter Hugo Howarth,D Jackson
出处
期刊:Pneumologie [Thieme Medical Publishers (Germany)] 日期:2026-03-01卷期号:80